Application
Western blot analysis of PLAUR using rabbit polyclonal PLAUR Antibody (W151) using 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the PLAUR gene.Application
Western blot analysis of PLAUR using rabbit polyclonal PLAUR Antibody (W151) using 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the PLAUR gene.Application
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. BC = breast carcinoma; HC = hepatocarcinoma.| Product Name | PLAUR Antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | Urokinase plasminogen activator surface receptor, U-PAR, uPAR, Monocyte activation antigen Mo3, CD87, PLAUR, MO3, UPAR |
| Product description | The urokinase-type plasminogen activator receptor is a key molecule in the regulation of cell-surface plasminogen activation and plays an important role in many normal as well as pathologic processes. The human PLAUR cDNA encodes 335 amino acids including a predicted signal peptide of 22 residues and a hydrophobic C-terminal portion.1 It produces a highly glycosylated protein of about 50 kD in monocytes where it is anchored to the plasma membrane by glycosyl-phosphatidylinositol linkage. PLAUR, also known as UPAR, is directly associated with the carbohydrate-binding domain of SELL in the membrane of neutrophils, an association analogous to that between PLAUR and beta-2 integrins.2 PLAUR-mediated calcium mobilization is SELL dependent. UPAR mRNA levels correlate with the invasive potential of endometrial carcinomas and show a 33-fold increase in UPAR mRNA levels in advanced clinical stage endometrial tumors compared with normal endometrial tissue.3 Furthermore, the increase in UPAR mRNA levels correlated linearly with the progression of disease stage. UPAR protein expressioin correlated positively with rate of recurrence and mortality in patients with endometrial cancer.4 UPAR appears to be a useful prognostic marker for advanced endometrial cancer.1) Borgfeldt, C., et al., Int. J. Cancer 107(4):658-665 (2003). |
| Immunogen | This PLAUR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 136-166 amino acids from the Central region of human PLAUR. |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | IHC-PWB |
| For IHC-P starting dilution is: 1:50~100 For WB starting dilution is: 1:1000: |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Symbol | PLAUR |
|---|---|
| Alternative Names | Urokinase plasminogen activator surface receptor U-PAR uPAR Monocyte activation antigen Mo3 CD87 PLAUR MO3 UPAR |
| Molecular Weight(MW) | 37 kDa |
| Sequence Similarities | Predicted species reactivity based on immunogen sequence: Monkey |
Application
Western blot analysis of PLAUR using rabbit polyclonal PLAUR Antibody (W151) using 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the PLAUR gene.
Application
Western blot analysis of PLAUR using rabbit polyclonal PLAUR Antibody (W151) using 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the PLAUR gene.
Application
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. BC = breast carcinoma; HC = hepatocarcinoma.| Application Notes | For IHC-P starting dilution is: 1:50~100 For WB starting dilution is: 1:1000: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Storage Buffer | Supplied in PBS with 0.09% (W/V) sodium azide. |
